Article Details

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

Retrieved on: 2021-03-11 17:37:30

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial. View article details on hiswai:

Excerpt

... mouse platforms, Harbour Mice®, which generates fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo